ABL001/Asciminib

Phase 2Small molecule

Novartis

ABL001/Asciminib is one of 3 small molecule programs targeting CML. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CMLRecruiting

CMLPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in CML

#DrugCompanyPhaseTrials

Iclusig

Takeda

Phase 2

2 2

Acetylsalicylic Acid

Bayer

Phase 2

1 3

ABL001/Asciminib

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

CML

NCT06514534

Clinical

Trials by Indication[1]

CML1 trial

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Recruiting· Novartis logo

Novartis·Phase 2·NCT06514534·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABL001/Asciminib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABL001/Asciminib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABL001/Asciminib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

ABL001/Asciminib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

CML1 trial

References

Drug Info

Quick Facts

Related News